Edwards Lifesciences Says PASCAL System Meets CLASP II TR Study Goal
Edwards Lifesciences said its PASCAL tricuspid repair system met the main goal in the CLASP II TR study.
Related stories
Papaya Owes $730 Million Judgment to Skillz Platform
M impact | EQUITY | Nov 02, 2026, 07:25 PM UTC
Tutor Perini unit wins $60 million Coast Guard contract
Tutor Perini said its subsidiary, Perini Man, received a $60 million US Coast Guard contract.
M impact | EQUITY | Nov 02, 2026, 07:22 PM UTC
US Equity Indexes Rise as Crude Oil and Treasury Yields Fall
M impact | EQUITY | Nov 02, 2026, 07:22 PM UTC
Meta plans potential bond sale to raise at least 200 hundred million dollars
Meta is planning a potential cross-border bond issue to raise at least 200 hundred million dollars, according to Bloomberg, Reuters reports.
M impact | EQUITY | Nov 02, 2026, 07:19 PM UTC
Lumentum shares fall more than 17%
Lumentum shares are down more than 17%, with Marvell weakness eroding the value of the all-stock takeover.
M impact | EQUITY | Nov 02, 2026, 07:19 PM UTC
報道：メタ、債券発行で少なくとも200億ドル調達を目指す
M impact | EQUITY | Nov 02, 2026, 07:19 PM UTC